2256 — Abbisko Medicine Share News
0.000.00%
Last trade - 00:00- HK$4.55bn
- HK$2.21bn
- CNY612.12m
Brief: Abbisko Cayman Enters Exclusive Out-License Agreement With Shanghai Allist Pharmaceuticals
Brief: Abbisko Cayman Says Unit Obtained Clinical Trial Approval For Absk121
Brief: Abbisko Cayman Says U.S. FDA Granted Breakthrough Therapy Designation For Unit's Drug
Brief: Abbisko Cayman Says Csf-1R Inhibitor, Pimicotinib (Absk021) Approved By Nmpa For Phase Ii Clinical Study
Brief: Abbisko Cayman Says Unit's FGFR Inhibitor ABSK121 Got U.S. FDA's Clinical Trial Approval
Brief: Abbisko Cayman Unit's CSF-1R Inhibitor Gets Phase III Trial Approval From China's NMPA
Brief: Abbisko Cayman HY Loss RMB221.6 Mln Vs Loss Of RMB377.2 Mln
Brief: Abbisko Cayman Says Unit Granted Therapy Designation By Center For Drug Evaluation Of NMPA
Brief: Abbisko Cayman Says Zhang Zidong Appointed As CFO
Brief: Abbisko Cayman Says Yeh Richard Resigned As Executive Director
Brief: Abbisko Cayman Says Oral Pd-L1 Inhibitor Received Clinical Trial Approval From Nmpa Of People's Republic Of China
Brief: Abbisko Cayman Says PAN-FGFR Inhibitor ABSK091 Got Orphan Drug Designation In U.S.
Brief: Abbisko Cayman Says Unit Obtained IND Approval For Absk061 From NMPA
Brief: Abbisko Cayman Says Unit Entered A Worldwide Collaboration And Exclusive Licensing Deal With Eli Lilly
Brief: Abbisko Cayman Says Unit Got Regulatory Approval From Food & Drug Administration Of U.S.
Brief: Abbisko Cayman Egts IND Approval From China's NMPA For Initiation Of A Phase II Clinical Trial Of Absk011